A detailed history of Israel Englander (Millennium Management LLC) transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Millennium Management LLC holds 13,700 shares of BMRN stock, worth $906,255. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,700
Previous 31,500 56.51%
Holding current value
$906,255
Previous $2.75 Million 59.03%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$74.43 - $92.22 $86.2 Million - $107 Million
-1,158,455 Reduced 50.87%
1,118,724 $92.1 Million
Q1 2024

May 15, 2024

BUY
$83.81 - $99.0 $92.9 Million - $110 Million
1,108,824 Added 94.9%
2,277,179 $199 Million
Q4 2023

Feb 14, 2024

BUY
$76.22 - $98.51 $63.9 Million - $82.5 Million
837,948 Added 253.61%
1,168,355 $113 Million
Q2 2023

Aug 14, 2023

BUY
$86.68 - $100.3 $68,650 - $79,437
792 Added 0.24%
330,407 $28.6 Million
Q1 2023

May 15, 2023

SELL
$87.74 - $117.27 $40 Million - $53.5 Million
-455,835 Reduced 58.03%
329,615 $32.1 Million
Q4 2022

Feb 14, 2023

SELL
$80.93 - $108.63 $88.1 Million - $118 Million
-1,088,822 Reduced 58.09%
785,450 $81.3 Million
Q3 2022

Nov 14, 2022

BUY
$82.16 - $96.94 $28.6 Million - $33.8 Million
348,269 Added 22.82%
1,874,272 $159 Million
Q2 2022

Aug 15, 2022

BUY
$71.48 - $86.85 $16 Million - $19.5 Million
224,011 Added 17.21%
1,526,003 $126 Million
Q1 2022

May 16, 2022

BUY
$74.28 - $92.69 $44.1 Million - $55.1 Million
593,956 Added 83.89%
1,301,992 $100 Million
Q4 2021

Feb 14, 2022

SELL
$71.72 - $91.47 $10.1 Million - $12.8 Million
-140,452 Reduced 16.55%
708,036 $62.6 Million
Q3 2021

Nov 15, 2021

BUY
$74.77 - $85.47 $60.4 Million - $69 Million
807,552 Added 1972.72%
848,488 $65.6 Million
Q2 2021

Aug 16, 2021

SELL
$75.51 - $84.79 $15.4 Million - $17.3 Million
-204,255 Reduced 83.3%
40,936 $3.42 Million
Q1 2021

May 17, 2021

SELL
$74.73 - $90.69 $16.9 Million - $20.5 Million
-226,302 Reduced 48.0%
245,191 $18.5 Million
Q4 2020

Feb 16, 2021

SELL
$72.61 - $90.2 $2.73 Million - $3.39 Million
-37,571 Reduced 7.38%
471,493 $41.3 Million
Q3 2020

Nov 16, 2020

BUY
$71.87 - $131.03 $26.9 Million - $49.1 Million
374,732 Added 278.96%
509,064 $38.7 Million
Q2 2020

Aug 14, 2020

SELL
$79.55 - $124.22 $7.49 Million - $11.7 Million
-94,130 Reduced 41.2%
134,332 $16.6 Million
Q1 2020

May 14, 2020

SELL
$71.37 - $96.85 $27.2 Million - $36.9 Million
-381,353 Reduced 62.54%
228,462 $19.3 Million
Q4 2019

Feb 14, 2020

BUY
$64.27 - $86.37 $23 Million - $30.9 Million
357,766 Added 141.94%
609,815 $51.6 Million
Q3 2019

Nov 14, 2019

SELL
$67.4 - $85.11 $10.7 Million - $13.6 Million
-159,380 Reduced 38.74%
252,049 $17 Million
Q2 2019

Aug 15, 2019

BUY
$80.35 - $93.9 $20.1 Million - $23.4 Million
249,664 Added 154.34%
411,429 $35.2 Million
Q2 2019

Aug 14, 2019

SELL
$80.35 - $93.9 $1.05 Million - $1.23 Million
-13,113 Reduced 7.5%
161,765 $1.19 Million
Q1 2019

May 14, 2019

BUY
$84.2 - $98.62 $5.77 Million - $6.76 Million
68,586 Added 64.53%
174,878 $15.5 Million
Q4 2018

Feb 14, 2019

SELL
$80.14 - $106.07 $18.3 Million - $24.2 Million
-228,550 Reduced 68.26%
106,292 $9.05 Million
Q3 2018

Nov 14, 2018

SELL
$93.92 - $105.72 $23.9 Million - $26.9 Million
-254,808 Reduced 43.21%
334,842 $32.5 Million
Q2 2018

Aug 14, 2018

SELL
$76.01 - $99.03 $4.24 Million - $5.52 Million
-55,750 Reduced 8.64%
589,650 $55.5 Million
Q1 2018

May 15, 2018

BUY
$77.67 - $92.63 $818,331 - $975,949
10,536 Added 1.66%
645,400 $52.3 Million
Q4 2017

Feb 14, 2018

BUY
$80.76 - $95.13 $12.9 Million - $15.2 Million
160,132 Added 33.73%
634,864 $56.6 Million
Q3 2017

Nov 14, 2017

BUY
$80.6 - $94.95 $38.3 Million - $45.1 Million
474,732
474,732 $44.2 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.3B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.